TRANSIENT INHIBITION OF ADENOSINE KINASE AS AN ANTI-EPILEPTOGENESIS TREATMENT

摘要

Methods of anti-epileptogenesis treatment in which adenosine kinase (ADK) activity or expression is inhibited only transiently to provide a long-term benefit to a non-epileptic or epileptic subject. In an exemplary method, a therapeutically effective amount of an ADK inhibitor may be administered to a human non-epileptic subject over a finite, predetermined treatment period having a duration of less than two months. The non-epileptic subject may have sustained a precipitating event with a known risk to trigger latent development of an acquired form of epilepsy. Administration of the ADK inhibitor to the subject may be stopped at the end of the treatment period for at least the longer of (i) six months and (ii) ten times the duration of the treatment period. The step of administering may reduce the chance of the subject having seizures caused by the acquired form of epilepsy for an extended period following the end of the treatment period.

主权项

1. A method of anti-epileptogenesis treatment, the method comprising:
administering a therapeutically effective amount of an adenosine kinase inhibitor to a human non-epileptic subject over a finite, predetermined treatment period having a duration of less than two months; wherein the non-epileptic subject has sustained a precipitating event with a known risk to trigger latent development of an acquired form of epilepsy in non-epileptic subjects, wherein the precipitating event occurred within three months of the start of the treatment period, wherein administration of the adenosine kinase inhibitor to the subject is stopped at the end of the treatment period for at least the longer of (i) six months and (ii) ten times the duration of the treatment period, and wherein the step of administering reduces the chance of the subject having seizures caused by the acquired form of epilepsy for a period following the end of the treatment period and lasting at least the longer of (i) six months and (ii) ten times the duration of the treatment period.